Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 20/20 | 1.00 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 1.00 |
| ▸ | KAT2A | Q92830 | 2/20 | 0.77 |
| ▸ | BPTF | Q12830 | 2/20 | 0.77 |
| ▸ | BRD1 | O95696 | 1/20 | 0.77 |
| ▸ | ACHE | P22303 | 1/20 | 0.77 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.77 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.77 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.77 |
| ▸ | BRPF3 | Q9ULD4 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17916738 | 1.00 | KAT2B (1.00) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL25049813 | 1.00 | KAT2B (1.00) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL17912355 | 1.00 | KAT2B (1.00) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL23718084 | 1.00 | KAT2B (1.00) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL30830592 | 0.89 | KAT2B (0.79) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL20805680 | 0.88 | KAT2B (0.78) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL30830640 | 0.87 | KAT2B (0.77) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL30830497 | 0.87 | KAT2B (0.77) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL23682859 | 0.87 | KAT2B (1.00) | KAT2BBRD9KAT2ABPTFBRD1 | |
| SCHEMBL23682853 | 0.87 | KAT2B (1.00) | KAT2BBRD9KAT2ABPTFBRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | KAT2B 36/4885BRD9 2265/4885KAT2A 88/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | KAT2B 2513/4885BRD9 2024/4885KAT2A 1197/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | KAT2B 2513/4885BRD9 2024/4885KAT2A 1197/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | KAT2B 645/4885BRD9 4029/4885KAT2A 260/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | KAT2B 735/4885BRD9 3664/4885KAT2A 395/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | KAT2B 1273/4885BRD9 472/4885KAT2A 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.